"The antiproliferative effect of lanreotide may support its place in the treatment algorithm for enteropancreatic NETs," Dr. Ruszniewski said.
In an interview, Dr. Öberg further commented that the CLARINET data show that "somatostatin analogues can be used for patients with all different subtypes of NET with a very low rate of side effects." If more aggressive therapy is needed, he added, then targeted treatment with drugs such as everolimus or chemotherapy may be needed. "The guidelines will change," he reiterated.
The study was sponsored by Ipsen. Dr. Ruszniewski has served as an adviser to Ipsen and received research funding from the company and from Novartis. Dr. Öberg has served as an adviser and speaker for Novartis, Ipsen, and Pfizer.
